In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and pept1 knockout mice

Pharmaceutical Research

Volumn 30, Issue 11, 2013, Pages 2931-2939

  Posada, Maria M ^a   Smith, David E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

cefadroxil; knockout mice; oral absorption; PepT1; tissue distribution

Indexed keywords

CEFADROXIL; PEPTIDE TRANSPORTER 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG TISSUE LEVEL; DRUG UPTAKE; GENOTYPE; IN VIVO STUDY; INTESTINE ABSORPTION; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; CEFADROXIL; GENE DELETION; INTESTINAL ABSORPTION; INTESTINES; MICE; MICE, KNOCKOUT; SYMPORTERS;

EID: 84886102035     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1168-3     Document Type: Article

References (35)

1. Brandsch M, Knutter I, Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008;60:543-85.
2. Rubio-Aliaga I, Daniel H. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica. 2008;38:1022-42.
3. Smith DE, Clemençon B, Hediger MA. Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol Aspects Med. 2013;34:323-36.
4. Yamashita T, Shimada S, Guo W, Sato K, Kohmura E, Hayakawa T, et al. Cloning and functional expression of a brain peptide/histidine transporter. J Biol Chem. 1997;272:10205-11.
5. Sakata K, Yamashita T, Maeda M, Moriyama Y, Shimada S, Tohyama M. Cloning of a lymphatic peptide/histidine transporter. Biochem J. 2001;356(Pt 1):53-60.
6. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998;15:1154-9.
7. Bretschneider B, Brandsch M, Neubert R. Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999;16:55-61.
8. Rubio-Aliaga I, Daniel H. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol Sci. 2002;23:434-40.
9. Buck RE, Price KE. Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1977;11:324-30.
10. Tanrisever B, Santella PJ. Cefadroxil: a review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine. Drugs. 1986;32 Suppl 3:1-16.
11. Marino EL, Dominguez-Gil A, Muriel C. Influence of dosage form and administration route on the pharmacokinetic parameters of cefadroxil. Int J Clin Pharmacol Ther Toxicol. 1982;20:73-7.
12. Tsuji A, Nakashima E, Kagami I, Yamana T. Intestinal absorption mechanism of amphoteric beta-lactam antibiotics I: comparative absorption and evidence for saturable transport of amino-beta-lactam antibiotics by in situ rat small intestine. J Pharm Sci. 1981;70:768-72.
13. de Waart DR, van de Wetering K, Kunne C, Duijst S, Paulusma CC, Oude Elferink RP. Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012;40:515-21.
14. Shen H, Smith DE, Yang T, Huang YG, Schnermann JB, Brosius 3rd FC. Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am J Physiol. 1999;276:F658-65.
15. Shen H, Smith DE, Keep RF, Brosius 3rd FC. Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in developing rat brain. Mol Pharm. 2004;1:248-56.
16. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest. 2002;82:193-201.
17. Ming X, Thakker DR. Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil. Biochem Pharmacol. 2010;79:455-62.
18. Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signaling molecules. Trends Pharmacol Sci. 2008;29:200-7.
19. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-36.
20. Sánchez-Picó A, Peris-Ribera JE, Toledano C, Torres-Molina F, Casabó VG, Martín-Villodre A, et al. Non-linear intestinal absorption kinetics of cefadroxil in the rat. J Pharm Pharmacol. 1989;41:179-85.
21. Garrigues TM, Martin U, Peris-Ribera JE, Prescott LF. Dose-dependent absorption and elimination of cefadroxil in man. Eur J Clin Pharmacol. 1991;41:179-83.
22. Shen H, Ocheltree SM, Hu Y, Keep RF, Smith DE. Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos. 2007;35:1209-16.
23. Posada MM, Smith DE. Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. Pharm Res. 2013;30:1017-25.
24. Hu Y, Smith DE, Ma K, Jappar D, Thomas W, Hillgren KM. Targeted disruption of peptide transporter Pept1 gene in mice significantly reduces dipeptide absorption in intestine. Mol Pharm. 2008;5:1122-30.
25. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. Philadelphia: Wolters Kluwer; 2011.
26. Jappar D, Wu SP, Hu Y, Smith DE. Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and Pept1 knockout mice. Drug Metab Dispos. 2010;38:1740-6.
27. Jappar D, Hu Y, Smith DE. Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice. Drug Metab Dispos. 2011;39:2250-7.
28. La Rosa F, Ripa S, Prenna M, Ghezzi A, Pfeffer M. Pharmacokinetics of cefadroxil after oral administration in humans. Antimicrob Agents Chemother. 1982;21:320-2.
29. McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol. 2008;60:63-70.
30. Yang B, Smith DE. Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. Drug Metab Dispos. 2013;41:608-14.
31. Ma K, Hu Y, Smith DE. Influence of fed-fasted state on intestinal PEPT1 expression and in vivo pharmacokinetics of glycylsarcosine in wild-type and Pept1 knockout mice. Pharm Res. 2012;29:535-45.
32. García-Carbonell MC, Granero L, Torres-Molina F, Aristorena JC, Chesa-Jiménez J, Plá-Delfina JM, et al. Nonlinear pharmacokinetics of cefadroxil in the rat. Drug Metab Dispos. 1993;21:215-7.
33. Mariño EL, Dominguez-Gil A. Influence of dose on the pharmacokinetics of cefadroxil. Eur J Clin Pharmacol. 1980;18:505-9.
34. Barbhaiya RH. A pharmacokinetic comparison of cefadroxil and cephalexin after administration of 250, 500 and 1000 mg solution doses. Biopharm Drug Dispos. 1996;17:319-30.
35. Ocheltree SM, Shen H, Hu Y, Keep RF, Smith DE. Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther. 2005;315:240-7.